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Background: Tuberculosis (TB) disease affects survival among HIV co-infected patients on antiretroviral therapy
(ART). Yet, the magnitude of TB disease on mortality is poorly understood.
Methods: Using a prospective cohort of 22,477 adult patients who initiated ART between August 2000 and June
2009 in Uganda, we assessed the effect of active pulmonary TB disease at the initiation of ART on all-cause
mortality using a Cox proportional hazards model. Propensity score (PS) matching was used to control for potential
confounding. Stratification and covariate adjustment for PS and not PS-based multivariable Cox models were also
performed.
Results: A total of 1,609 (7.52%) patients had active pulmonary TB at the start of ART. TB patients had higher
proportions of being male, suffering from AIDS-defining illnesses, having World Health Organization (WHO) disease
stage III or IV, and having lower CD4 cell counts at baseline (p < 0.001). The percentages of death during follow-up
were 10.47% and 6.38% for patients with and without TB, respectively. The hazard ratio (HR) for mortality
comparing TB to non-TB patients using 1,686 PS-matched pairs was 1.37 (95% confidence interval [CI]: 1.08 – 1.75),
less marked than the crude estimate (HR = 1.74, 95% CI: 1.49 – 2.04). The other PS-based methods and not PS-based
multivariable Cox model produced similar results.
Conclusions: After controlling for important confounding variables, HIV patients who had TB at the initiation of
ART in Uganda had an approximate 37% increased hazard of overall mortality relative to non-TB patients.
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The total number of people living with human immuno-
deficiency virus (HIV) reached 34.0 million (31.6 – 35.2
million) worldwide by the end of 2010, [1] with the ma-
jority in Sub-Saharan Africa. One-third of HIV-infected
people are estimated to be co-infected with Mycobacter-
ium tuberculosis (TB) which can activate or reactivate
during the initiation of antiretroviral therapy (ART) due
to immune reconstitution inflammatory syndrome (IRIS).
However, TB incidence rates vary according to geography* Correspondence: thabanl@mcmaster.ca
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reproduction in any medium, provided the orand patients’ degrees of immunosuppression. The inci-
dence proportion of active TB in HIV-infected patients
with latent TB infection is about 10% per year compared
to 10% per lifetime for an HIV-uninfected individual [2].
TB is a leading cause of HIV-related death [3]. Recent trial
data have shown that early initiation of ART (within two
weeks) during TB therapy can improve survival for pa-
tients with co-infection [4-6]. Guidelines and policies on
joint HIV/TB interventions have been developed to pro-
mote synergies between TB and HIV/AIDS prevention
and care activities, [7-9] aimed at reducing morbidity and
mortality in co-infected patients. On the other hand, joint
treatment containing ART and anti-TB drugs may be
complicated by overlapping toxicity profiles, complex
drug-drug interactions, and IRIS [10-13].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tality in HIV-infected patients who receive ART is
poorly understood, particularly in settings with a rela-
tively lower TB prevalence, such as Eastern Africa
[9,13,14]. An observational study from Tororo, Uganda,
comprising 1,044 HIV patients showed that TB at the
initiation or during follow-up of ART was associated
with a 4.7-fold increase in cumulative mortality relative
to those without TB [15]. Nevertheless the association of
TB disease and mortality was clearly confounded by de-
gree of immunosuppression [15,16]. Several studies in
more developed countries suggest incident TB substan-
tially increases the risk of AIDS-related mortality among
HIV patients receiving ART [17,18]. A recent meta-
analysis suggested little impact of TB on mortality in HIV
patients receiving ART [19]. Small numbers of co-infected
patients, different procedures of baseline confounding ad-
justment, and incomplete information on clinical outcomes
have led to uncertainty of the impact of active TB on subse-
quent mortality among co-infected patients on ART and
the optimal timing of treatment of both diseases.
Our study involved a large prospective cohort of HIV-
infected adult patients in Uganda, and had two objectives:
(1) to assess the effect of active pulmonary TB disease at
ART initiation on overall survival among HIV patients
during ART treatment by adjusting for potential con-
founders using propensity score (PS) methods, [20-22]
and (2) to explore the robustness of the study findings by
comparing results from three PS methods (matching on
PS, stratifying on PS, adjusting for PS as regression covari-
ate) to conventional (not PS-based) multivariable Cox re-
gression model. These results may help accurately plan
TB and HIV/AIDS management activities in HIV patients
with TB co-infection.
Methods
Setting, participants and data collection
Our prospective cohort contained HIV-infected patients
initiating ART at ten service centres managed by the
AIDS Support Organization (TASO) across different set-
tings in Uganda since 2000. Patients received ART from
experienced medical staff at TASO clinics, outreach
clinics in rural areas, and through community-based
treatment programs. Details of the treatment program
have been published previously [23]. The standard regi-
men was two nucleoside reverse transciptase inhibitors
and one non-nucleoside reverse transcriptase inhibitor.
The current study included adult patients (aged 14 years
or older at ART initiation) enrolled between August 2000
and June 2009 (inclusive) as part of an ongoing observa-
tional study intended to evaluate the programmatic deliv-
ery of services. After ART initiation, patients were
scheduled for clinic visits at least every three months. Pa-
tients’ demographic, clinical, psychosocial, and medicationuse data were collected by clinicians, and field workers
using standardized forms at ART initiation, and each visit.
At the time of data collection, national guidelines in
Uganda used three strategies for initiating treatment of
TB in a co-infected patient: (1) patient with TB and CD4
cell count < 250 cells/mm3 or a patient with extra-
pulmonary TB or WHO stage IV disease: start TB ther-
apy first and when tolerated (usually within two to six
weeks) then introduce ART; (2) pulmonary TB and CD4
250–350 cells/mm3: start TB therapy for two months
then introduce ART, and; (3) pulmonary TB and CD4 >
350 cells/mm3: defer ART, monitor clinically and also do
CD4 cell counts regularly; re-evaluate the patient at eight
weeks and the end of TB treatment [24].
Primary outcome, exposure and potential
confounding variables
Our primary outcome was time from the initiation of
ART to death for any reason after the initiation of ART
between August 2000 and June 2009. The primary ex-
posure was active pulmonary TB as evidenced by spu-
tum smear-positive results at the initiation of ART, or
suspected TB regardless of sputum results followed up
by radiography. Fourteen variables containing clinical
and demographic characteristics and medicine history
measured at the beginning of ART (baseline), were consid-
ered in the study and their roles as potential confounders
were investigated. The 14 baseline covariates were gender,
age, CD4 count, World Health Organization (WHO) clin-
ical disease stage of HIV/AIDS, presence of AIDS-defining
illness, TASO service centre, calendar year of ART initi-
ation, education, marital status, partner sero-status, sexual
activity, sexually transmitted infection, history of pneumo-
cystis pneumonia (PCP), and toxoplasmosis. A potential
confounder was defined here as a baseline covariate that
was likely to associate with the overall survival and base-
line disease status of TB. The assessment of association
between the covariates and the outcome was primarily
based on published literature [25-29]. We also hypothe-
sized the associations between overall survival and some
covariates that pertained to the study setting. For example,
the variation in political and socioeconomic factors and
unmet demand for healthcare workers across the 10
Ugandan study sites were likely to result in difference in
patient outcomes [30]. Patient sexual dynamics could po-
tentially affect prevention and treatment for HIV/AIDS in
African countries [31-34]. Literature suggested that people
with weak immune systems were generally more likely to
have active TB disease [35]; and among HIV patients, male
gender, low CD4 count, high viral load, severe disease
stage, and low socioeconomic status were possible risk fac-
tors of active TB disease. We carefully examined the distri-
butions of the 14 covariates between TB and non-TB
groups at baseline (see “Statistical analysis” section). We
Chu et al. AIDS Research and Therapy 2013, 10:19 Page 3 of 11
http://www.aidsrestherapy.com/content/10/1/19analyzed age and CD4 count as continuous variables, and
the other 12 covariates as categorical data coded by a ref-
erence level and dummy indicators (Additional file 1).
Statistical analysis
We adopted PS methods to control for confounding,
and estimated the causal effect of TB at the initiation of
ART on overall survival of HIV patients since their
initiation of ART using Cox regression models. We
reported the crude and adjusted effects of TB using
hazard ratios [HRs]. A patient was censored at the time
they were lost to follow-up, or at the end of the study if
still alive. PS methods have been increasingly used to
control for baseline confounding in observational studies
[20-22,36-40]. PS methods are more advantageous than
adjusting for multiple covariates simultaneously in a single
outcome model when numerous confounders need to be
accounted for and the outcome is rare. PS methods
provide an easy means to compare distributions of
confounding variables between exposure groups within
PS-stratified sets. It can be difficult to examine balancing
distributions of confounders post-adjustment using the
conventional multiple regression methods. We chose
Cox regression on PS-matched pairs as the primary
method of analysis because empirical evidence suggested
PS-matching provides better control for confounding
than other PS methods, [41,42] and statistical diagnostic
tools for assessing the balance of confounders between
PS-matched pairs were readily available [40,43,44]. Spe-
cifically, we fit a Cox proportional hazards (PH) model
in a dataset containing 1,686 TB cases and 1,686 PS-
matched non-TB patients to control for observed potential
confounding using a two-step procedure. First, we modeled
the relationship between having active TB at baseline and
the observed baseline covariates using a logistic regression
model (“PS model”). We employed an iterative approach
[45] to build the PS model by starting with the 14 observed
baseline covariates; we then considered pairwise interac-
tions, and polynomial terms of the continuous variables
(age and CD4 cell count) in the PS model. We ultimately
included such terms in the model if adding them improved
the predictive power of the PS model and its ability to
balance covariates between PS-matched pairs. Greater
predictive power of the PS model (i.e. how well covari-
ates included in the PS model predict baseline TB dis-
ease status) was likely to result in greater balance; the
performance of matching was also affected by other
factors such as the matching algorithm and associated
tuning parameters (e.g. caliper width). We aimed to
match each active TB patient to one non-TB patient
with the closest logit of the estimated PS, within a cali-
per of 0.2 of the standard deviation of the logit of the
estimated PS [46]. This matching method was shown
to lead to optimal estimation of exposure effects invarious simulation settings [41,47]. Propensity score is
a balancing score, so we assessed PS model adequacy
(selection of variables and functional form) based on
examining the similarity of the joint distribution of
multiple baseline covariates between TB and non-TB
patients with the same estimated propensity score [42].
Balance diagnostics of baseline covariates consisted of
a series of numerical and graphical measures, including
standardized difference, and for continuous covariates,
ratio of variance, five-number summaries, quantile-quantile
plot, nonparametric density plot, empirical cumulative
distribution function and side-by-side boxplot. We repeated
the PS modeling – balance diagnostics steps until we were
satisfied with the resulting balancing distribution. Second,
we fit a stratified Cox PH model to estimate the impact of
baseline TB on survival. As outcomes within PS-matched
pairs are not independent, we stratified on pairs to controls
for within-pair homogeneity, allowing baseline hazard
functions to vary across matched strata [45,48]. The
appropriateness of the PH assumption was assessed
using log-log survival curves.
We applied two other PS methods for confounding
control as supportive secondary analyses to assess the
robustness of the results of the primary analysis, namely,
stratified Cox regression on quintiles of the estimated
PS, and a Cox model adjusting for PS and its quadratic
and cubic terms as covariates. Conventional (not PS-
based) Cox regression directly modeling the effect of TB
on overall survival, adjusting for multiple baseline covar-
iates in the same form as included in the final PS model,
was also performed.
Complete information was recorded for the study sam-
ple on TB status at ART initiation and on all but four
baseline covariates, namely, age (8% missing), CD4 count
(17.3% missing), sexual activity (17.3% missing) and
WHO stage of HIV/AIDS (34.4% missing). Excluding pa-
tients with missing data on any of the covariates would
have led to a loss of 48% of subjects and 86% of death
events. Such exclusions could have affected the stability
of statistical models (PS-based or not) due to low event
rate and jeopardized the internal validity and gen-
eralizability of the study. Therefore, we performed all
analyses on five multiple imputation (MI) datasets [49].
We used Markov chain Monte Carlo method assuming
multivariate normality to create a monotone missing
pattern, followed by separate imputations for the con-
tinuous (age, log CD4 count) and categorical (sexual
activity and stage of disease) variables using linear and
logistic regression models. A number of baseline char-
acteristics (TB status, gender, TASO sites, AIDS status,
education level, marital status, partner sero-status,
sexually transmitted infection, calendar year of ART
initiation, and history of PCP or toxoplasmosis) and
follow-up variables (death, regimen switch, patient
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included in the imputation procedure. The follow-up
variables were assessed after the initiation of ART and
before the end of the study (death, lost to follow-up or
June 2009, whichever happened first). Patient adherence
was assessed at two weeks, two months and thereafter at
six months after ART initiation, based on a composite of
pharmacy monitored drug possession ratio, pharmacy
refill records, and a three day recall report by patients
or care givers. TASO calculated the mean adherence to
ART for each patient. Adequate clinical adherence was
defined as ≥95% (i.e. adherence = yes; Additional file 1)
[50,51]. No post-ART variables were included in PS or
Cox regression models as they could be causal inter-
mediates between baseline TB status and death, and
accounting for them in the models could induce bias.
While the same covariates were used to achieve prog-
nostic balance on the five imputed datasets, propensity
scores and baseline TB – mortality association were
estimated separately for each individual dataset. We
then calculated the overall estimate of TB effect, using
Rubin’s rule [49].
We conducted statistical analyses in SAS version 9.2
(Cary, NC), R 2.14.0 (R Core Development Team) and
Stata 10 (College Station, TX).
Ethics approval
University of British Columbia, University of Ottawa, and
Mbale Regional Referral Hospital research ethics boards
approved this study.
Results
Participant baseline characteristics
The study cohort consisted of 22,477 HIV-infected adult
patients aged 14 years or older who started ART between
August 2000 and June 2009 (Additional file 2: Figure S1).
A total of 1,690 of 22,477 patients (7.52%) had active pul-
monary TB disease at the initiation of ART. Table 1 indi-
cates TB patients had lower CD4 counts (p < 0.001) and
more advanced clinical stages (p < 0.001) at the start of
ART. TB patients tended to be younger, had higher pro-
portions of male, AIDS-defining illnesses, and a history of
PCP (p < 0.001). Higher proportions of the TB patients
were managed by the Entebbe, Jinja, Tororo and Mulago
regional centres, whereas higher proportions of the non-
TB patients were observed in Masaka, Mbale, Mbarara,
Masindi, and Soroti regions. Summary statistics of the four
baseline covariates with missing values was similar in the
original and imputed datasets (Additional file 3).
Association between TB at ART initiation and
baseline covariates
The final PS model included all 14 baseline covariates,
their pairwise interactions with gender and baselineAIDS status (yes or no), and additional quadratic and
interaction terms for the continuous variables to im-
prove model fit (Additional file 4). Overall, the PS model
predicted baseline TB status well (c statistic = 0.744, p-
value = 0.203 for Hosmer and Lemeshow goodness-of-fit
test). We were able to match 1,686 of 1,690 baseline TB
patients to non-TB patients. PS matching improved the
similarity of the distributions of all baseline covariates
between TB and non-TB patients and reduced the stan-
dardized differences to below 0.1. Table 2 displays the
balancing distributions of the baseline covariates for one
of the five imputed datasets. Consistent patterns were
observed across the imputed datasets. Additional details
on specific balance diagnostics of the two continuous
covariates are in the appendices (Additional file 5: Figure
S2 and Additional file 6: Figure S3).
Association between TB and all-cause mortality
During a median of 21.5 months of follow-up, 1,503
(6.69%) of the 22,477 HIV patients died. The propor-
tions of patients who died with and without TB were
10.47% (median length of follow-up [IQR]: 627.5 days
[205–1034]) and 6.38% (median length of follow-up
[IQR]: 646 days [306–1045]), respectively, in the original
unmatched sample. The proportion of deaths remained
higher in the 1,686 PS-matched pairs, with 176 (10.44%;
median length of follow-up [IQR]: 629 [205–1036]) and
137 (8.13%; median length of follow-up [IQR]: 659
[286–1023]) deaths in the TB and non-TB groups. An
unadjusted Cox model suggested that TB, relative to no
TB, increased the hazard of death by 74% (HR = 1.74,
95% CI: 1.49 – 2.04). The HR for all-cause mortality
comparing TB to non-TB patients on the 1,686 PS-
matched pairs (HR = 1.37, 95% CI: 1.08 – 1.75) was less
substantial, indicating TB was associated with a 37%
increase in the hazard of death over the course of the
study after controlling for potential baseline confounding
variables (Table 3). The PS-matched estimate was less
precise than the crude due to a decrease of sample size.
Kaplan-Meier survival curves for the original sample
and PS-matched pairs are displayed in Figures 1 and 2.
No violation of the PH assumption was suggested by
log-log survival curves.
Additional analyses
Stratifying on PS quintiles and adjusting for PS as a covar-
iate in Cox regression models yielded similar TB effects
on survival (PS-stratified HR= 1.36, 95% CI: 1.15-1.60;
PS-adjusted HR = 1.34, 95% CI: 1.14 -1.58) (Table 3).
Adjusting for multiple baseline covariates simultaneously
in the conventional not PS-based Cox model did not alter
the association substantially (HR = 1.40, 95% CI: 1.19-
1.65). Ratios of the widths of the 95% CIs are presented in
Table 3. HR estimates using the alternative adjustment
Table 1 Comparison of baseline and follow-up characteristics between HIV-infected patients with and without co-infection
of tuberculosis in the unmatched sample with imputed covariates (for a single multiple imputation dataset)
Characteristics TB: yes TB: no P-value Standardized difference
(n = 1690) (n = 20787) (Ratio of variance for
continuous covariate)
Baseline characteristics
Demographics
Age (year)
Mean (SD) 36.87 (8.78) 37.93 (9.48) <0.0001 −0.117 (0.86)
Min 14 14
25th percentile 31 31
50th percentile 36 37
75th percentile 42 43
Max 73 93
Male: n (%) 670 (39.64) 6216 (29.90) <0.0001 0.206
HIV severity
CD4 count
Mean (SD) 143.39 (149.94) 170.82 (172.26) <0.0001 −0.170 (0.76)
Min 0 0
25th percentile 45 66
50th percentile 111 139
75th percentile 193 208
Max 1701 1983
WHO stage: n (%)
1 43 (2.54) 992 (4.77) <0.0001 -
2 441 (26.09) 11013 (52.98)
3 999 (59.11) 7173 (34.51)
4 207 (12.25) 1609 (7.74)
AIDS: n (%) 493 (29.17) 3881 (18.67) <0.0001 0.248
History of drug use & illnesses: n (%)
Pneumocystis pneumonia 28 (1.66) 101 (0.49) <0.0001 0.114
Toxoplasmosis 11 (0.65) 101 (0.49) 0.3542 0.022
Sexually transmitted infection 341 (20.17) 4353 (20.94) 0.4578 −0.019
Partner information: n (%)
Married poly 125 (7.40) 1801 (8.66) 0.0734 −0.047
Partner sero-positive 417 (24.67) 5801 (27.91) 0.0043 −0.073
Sexually active 1224 (72.43) 15272 (73.47) 0.3508 −0.023
Other characteristics: n (%)
Site
ENT 378 (22.37) 1950 (9.38) <0.0001 -
GUL 161 (9.53) 1891 (9.10)
JIN 276 (16.33) 2586 (12.44)
MAS 130 (7.69) 2246 (10.80)
MBL 144 (8.52) 2446 (11.77)
MBR 116 (6.86) 2641 (12.71)
MSD 61 (3.61) 1254 (6.03)
MUL 211 (12.49) 2390 (11.50)
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Table 1 Comparison of baseline and follow-up characteristics between HIV-infected patients with and without co-infection
of tuberculosis in the unmatched sample with imputed covariates (for a single multiple imputation dataset) (Continued)
SOR 29 (1.72) 1546 (7.44)
TOR 184 (10.89) 1837 (8.84)
Education (Higher institute) 58 (3.43) 623 (3.00) 0.3158 0.025
ART start year since 2000
0 0 (0) 2 (0.01) <0.0001 -
4 23 (1.36) 946 (4.55)
5 453 (26.80) 4532 (21.80)
6 373 (22.07) 3627 (17.45)
6 507 (30.00) 6715 (32.30)
8 330 (19.53) 4943 (23.78)
9 4 (0.24) 22 (0.11)
Follow-up characteristics
Death: n (%) 177 (10.47) 1326 (6.38) <0.0001 0.148
Median (IQR) length of follow-up (days) 627.5 (205–1034) 646 (306–1045) - -
Note: For continuous variables, mean and standard deviation for each group, standardized mean difference and ratio of variances between TB and no-TB patients
are reported. For categorical variables, frequency and percentage of the specified level, and standardized difference between TB and no-TB patients are reported,
unless noted otherwise. MI multiple imputation, SD standard deviation, WHO World Health Organization, HIV human immunodeficiency virus, AIDS acquired
immune deficiency syndromes, ENT Entebbe, JIN: Jinja, MAS Masaka, MBL Mbale, MBR Mbarara, MUL Mulago, TOR Tororo, GUL Gulu, SOR Soroti, MSD Masindi, IQR
interquantile range.
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PS-matched analysis, as the latter only utilized data from
the matched pairs, a subset of the study sample. The
trade-off between accuracy and precision of the PS
methods has been noted in previous studies [40,42].
Discussion
This is, to our knowledge, the largest cohort of HIV-
infected patients receiving ART in a single African coun-
try that has evaluated mortality outcomes in co-infected
patients. Descriptive analysis showed that TB patients,
compared to non-TB patients, were more likely to be
immunosuppressed, have a history of opportunistic
infections, and live in particular geographical regions
of Uganda. The results of Cox PH analysis using PS
matching for confounding control showed that having
pulmonary TB disease at the initiation of ART led to
a 37% increase in the hazard of all-cause mortality
during the follow-up period between 2000 and 2009.
Additional analyses using two other PS methods and
the conventional (not PS-based) multivariable Cox re-
gression model showed similar results. These analyses
may be viewed as sensitivity analyses because differ-
ent methods use different assumptions and the results
seem to remain robust to different ways of adjusting
for baseline confounding.
The prevalence of active pulmonary TB at the initi-
ation of ART of 7.52% in the study is consistent with
results from a smaller TASO cohort reported fromTororo, Uganda [15]. This indicates that TB is less
prevalent in Uganda compared with other African coun-
tries, particularly Southern Africa [16]. An open cohort
of 7,512 patients receiving ART in South Africa sug-
gested that 15.9% of HIV patients were treated for pul-
monary TB at ART initiation between 2004 and 2007.
Our finding of a 37% increase in hazard of overall mor-
tality associated with having active TB at ART initiation
after controlling for potential baseline confounding is
both statistically significant and clinically relevant. This
result is different from Westreich et al.’s findings on
7,512 HIV patients in South Africa, indicating pulmon-
ary TB treatment at ART initiation was uncorrelated to
the overall survival (HR = 1.06, 95% CI: 0.75-1.49) after
adjusting for multiple confounders [16]. While all TB
patients in the South Africa study received ART soon
after initiation of TB treatment if TB treatment was well
tolerated, the current study did not have reliable data on
TB treatment at the initiation of ART. Instead the effect
of baseline active pulmonary TB disease on mortality
was evaluated and active TB patients might or might not
have received TB treatment during the course of the
study. The difference in baseline exposure between the
two studies is likely to be the most important factor
explaining the different results and suggests a benefit of
starting TB treatment at ART initiation to reduce overall
mortality in a co-infected population.
Guidelines on the treatment of TB co-infection with
HIV have changed dramatically over the last few years
Table 2 Comparison of baseline and follow-up characteristics between HIV-infected patients with and without co-infection
of tuberculosis in propensity score matched pairs with imputed covariates (for a single multiple imputation dataset)
Covariate TB: yes TB: no Standardized difference
(n = 1686) (n = 1686) (Ratio of variance for
continuous covariate)
Baseline characterstics
Demographics
Age (year)
Mean (SD) 36.89 (8.77) 36.93 (8.87) −0.005 (0.978)
Min 14 14
25th percentile 31 31
50th percentile 36 36
75th percentile 42 42
Max 73 77
Male: n (%) 668 (39.62) 673 (39.92) −0.006
HIV severity
CD4 count
Mean (SD) 143.70 (149.98) 144.34 (139.78) −0.004 (1.15)
Min 0 0
25th percentile 45 44
50th percentile 112 118
75th percentile 194 196
Max 1701 1247
WHO stage: n (%)
1 43 (2.55) 43 (2.55) -
2 441 (26.16) 436 (25.86)
3 996 (59.07) 983 (58.30)
4 206 (12.22) 224 (13.29)
AIDS: n (%) 489 (29.00) 479 (28.41) 0.013
History of drug use & illnesses: n (%)
Pneumocystis pneumonia 25 (1.48) 33 (1.96) −0.037
Toxoplasmosis 11 (0.65) 8 (0.47) 0.024
Sexually transmitted infection 340 (20.17) 339 (20.11) 0.001
Partner information: n (%)
Married poly 125 (7.41) 136 (8.07) −0.024
Partner sero-positive 417 (24.73) 431 (25.56) −0.019
Sexually active 1221 (72.42) 1223 (72.54) −0.003
Other characteristics: n (%)
Site
ENT 374 (22.18) 378 (22.42) -
GUL 161 (9.55) 176 (10.43)
JIN 276 (16.37) 271 (16.07)
MAS 130 (7.71) 125 (7.41)
MBL 144 (8.54) 160 (9.49)
MBR 116 (6.88) 121 (7.18)
MSD 61 (3.62) 62 (3.68)
MUL 211 (12.51) 203 (12.04)
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Table 2 Comparison of baseline and follow-up characteristics between HIV-infected patients with and without co-infection
of tuberculosis in propensity score matched pairs with imputed covariates (for a single multiple imputation dataset)
(Continued)
SOR 29 (1.72) 18 (1.07)
TOR 184 (10.91) 172 (10.20)
Education (Higher institute) 58 (3.44) 59 (3.50) −0.003
ART start year since 2000
4 23 (1.36) 15 (0.89) -
5 452 (26.81) 428 (25.39)
6 372 (22.06) 360 (21.35)
7 505 (29.95) 548 (32.50)
8 330 (19.57) 330 (19.57)
9 4 (0.24) 5 (0.30)
Follow-up characteristics
Death: n (%) 176 (10.44) 137 (8.13) 0.080
Median (IQR) length of follow-up (days) 629 (205–1036) 659 (286–1023) -
Note: For continuous variables, mean and standard deviation for each group, standardized mean difference and ratio of variances between TB and no-TB patients
are reported. For categorical variables, frequency and percentage of the specified level, and standardized difference between TB and no-TB patients are reported,
unless noted otherwise. MI multiple imputation, SD standard deviation, WHO World Health Organization, HIV human immunodeficiency virus, AIDS acquired
immune deficiency syndromes, ENT Entebbe, JIN Jinja, MAS Masaka, MBL Mbale, MBR Mbarara, MUL Mulago, TOR Tororo, GUL Gulu, SOR Soroti, MSD Masindi, IQR
interquantile range.
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ample, early guidelines feared drug interactions between
TB medication and ART or negative impact on adherence
of ART or TB due to pill burden and suggested early
treatment for TB disease followed by stabilization with
ART. However, more recent evidence from randomized
trials [4-6] suggests that starting ART within two weeks
of TB treatment to improve survival appears to be well
tolerated, and has persuaded guideline makers to recom-
mend co-administration of treatment. In addition, re-
cent data from South Africa found that although IRIS
events were associated with slightly lower adherence
rates, overall adherence to ART remained high in this
co-infected population. The data suggested that con-
cerns about IRIS or drug-drug interactions should not
deter clinicians from early ART initiation, but patients
developing IRIS events should be monitored closely
and potentially targeted for interventions to increaseTable 3 Effect of tuberculosis (TB) at the initiation of antiretr
Method HR
Primary analysis
Matching on PS 1.37
Additional analyses
Unadjusted Cox regression 1.74
Stratified on PS 1.36
PS as covariate (linear, quadratic and cubic terms) 1.34
Conventional adjusted Cox regression 1.40
Results for the propensity score (PS) or covariate-adjusted Cox regression models w
HR hazard ratio, CI confidence interval, PS propensity score. * Reference = width ofadherence [52]. Other developments are related to the
specific setting. Uganda, for example, has a lower na-
tional prevalence of co-infection than Southern Africa
and has not reported any cases of extensively drug re-
sistant (XDR) TB infections. South Africa, on the other
hand, has had an epidemic of XDR co-infections that
has resulted in quarantine of some patients and recom-
mendations about interacting with other individuals [53].
National guidelines from Uganda do not match those of
South Africa, as discussed earlier.
Limitations of the study emerge from three key
sources. First, propensity score methods cannot balance
unmeasured confounders in estimating a causal relation-
ship, which is an issue faced by all observational cohorts.
Our results may be biased if some unobserved prognos-
tic factors were unbalanced between TB and non-TB
groups. While some studies examined the impact of
body mass index and anemia on clinical outcomes in co-oviral therapy (ART) on overall survival
95% CI P-value CI width ratio*
(1.08, 1.75) 0.011 1
(1.49, 2.04) <0.001 0.82
(1.15, 1.60) <0.001 0.66
(1.14, 1.58) <0.001 0.65
(1.19, 1.65) <0.001 0.69
ere aggregated across five multiple imputation datasets using Rubin’s rule.
95% CI for PS-matched estimate.
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Figure 1 Kaplan–Meier survival curves by baseline TB status in
the unmatched study sample.
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http://www.aidsrestherapy.com/content/10/1/19infected patients [16], such baseline information was un-
available in the current study. More resources need to
be dedicated to improve the completeness and accuracy
of data collection in HIV patients in underdeveloped
regions. Although statistical tools instrumental vari-
able analysis, have been developed to control for bias
due to unmeasured confounders [54], strong assump-
tions are required to ensure estimation accuracy, and
such assumptions can be difficult to verify using em-
pirical data. Second, the multiple imputation method
employed to impute the missing values for baseline co-
variates requires missing at random (MAR) assump-
tion (i.e. missingness can be explained by differences in
the observed data). Although the current imputation
procedure included a number of baseline characteristics
and follow-up variables, we could not rule out the exist-
ence of additional variables that were highly associated
with missingness. The MAR assumption is unverifiable
using data collected within a study. Third, our results are0.
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Figure 2 Kaplan–Meier survival curves by baseline TB status in
propensity score matched pairs for a single multiple imputation
dataset.predominantly based on adult, HIV-infected, African pa-
tients who initiated ART in Uganda, during 2004 to 2009,
hence limiting their generalizability. The effect of active
pulmonary TB disease on HIV patients in other age or
ethnic groups (for instance, children and adolescents)
and from different geographic regions should be fur-
ther investigated.
Our study shows a 37% increase in the hazard of death
among co-infected patients compared with those only
infected with HIV. We used pulmonary TB disease as
documented through sputum and radiologic confirmation
for the diagnosis of TB disease as TASO, along with most
AIDS service organizations in Africa, lacked the infrastruc-
ture to consistently diagnose extra-pulmonary TB disease.
Also, we recognize that sensitivity of sputum smear for
diagnosis of pulmonary TB in HIV-infected patients was
poor (less than 50%) and thus we followed up patients with
suspect TB disease with radiologic examinations regardless
of sputum results. Because TB is associated with mortality
(as observed in this study), misclassifying actual active TB
patients into the non-TB group would attenuate the magni-
tude of the TB effect on death; as a result the apparent esti-
mates of TB effects on death would be less substantial than
the actual effects.
Conclusions
In summary, our current study suggests a moderate in-
crease in the hazard of death associated with having active
TB disease at the initiation of ART in HIV-infected pa-
tients receiving ART in Uganda. Our finding is comple-
mentary to results of the recent SAPIT, [4] CAMELIA, [5]
and STRIDE trials [6] that demonstrate improved survival
when ART is initiated during TB therapy. The results also
validate the WHO guidelines that urge a more aggressive
approach to management of both TB and HIV [55].Additional files
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